Trials / Withdrawn
WithdrawnNCT02847013
The Use of Liposomal Bupivacaine in TAP Blocks for Women Undergoing Cesarean Section
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Milton S. Hershey Medical Center · Academic / Other
- Sex
- Female
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This present investigation aims to determine whether a transversus abdominous plane(TAP) block, utilizing liposomal bupivacaine (Exparel), at the conclusion of a cesarean section decreases post-operative pain. The hypothesis is that performance of the TAP block with liposomal bupivacaine will decrease post-operative narcotic use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAP block w Liposomal bupivacaine | TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs) |
| PROCEDURE | TAP block w normal saline | TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs) |
Timeline
- Primary completion
- 2019-12-17
- First posted
- 2016-07-27
- Last updated
- 2020-01-31
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02847013. Inclusion in this directory is not an endorsement.